|
|
Precisely Shaped Acoustic Ablation of Tumors Under 3D Ultrasound Image Guidance
|
1R44CA134169-01A1
|
$150,000
|
$150,000
|
Burdette, Everette
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
|
Experimental Models for Testing Novel Targets for Pancreatic Cancer Cell Invasion
|
1R21CA124931-01A1
|
$167,475
|
$167,475
|
MOUSA, SHAKER
|
ALBANY COLLEGE OF PHARMACY
|
|
|
A Novel Non-Invasive CRC Test Based on Mass Spec Of In Vitro Expressed Proteins
|
5R44CA119565-03
|
$455,651
|
$455,651
|
Han, James
|
AMBERGEN, INC
|
|
|
Novel RNA Markers for Detecting Colon Cancer Metastasis
|
1R43CA130238-01A2
|
$277,748
|
$277,748
|
Beaudenon, Sylvie
|
AMBION DIAGNOSTICS, INC.
|
|
|
Improving colonoscopic miss rate by real time microvascular blood analysis
|
4R42CA130508-02
|
$394,745
|
$394,745
|
Roy, Hemant
|
AMERICAN BIOOPTICS, LLC
|
|
|
RTOG Tissue Bank
|
5U24CA114734-04
|
$793,026
|
$158,605
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
American College of Radiology Imaging Network
|
2U01CA080098-10
|
$9,101,961
|
$2,503,039
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
QUALITY RESEARCH IN RADIATION ONCOLOGY: ACR PCS
|
5R01CA065435-10
|
$740,839
|
$148,168
|
WILSON, JESSE
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Adenoviral GFP targeting of metastatic human tumors using multiple delivery route
|
1R43CA132242-01
|
$149,575
|
$149,575
|
Kishimoto, Hiroyuki
|
ANTICANCER, INC.
|
|
|
402 - RFP: N43-CM-87007-68 TOPIC 251: DEVELOPMENT OF ANTICANCER AGENTS REQUEST
|
N43CM800026-000
|
$149,558
|
$149,558
|
CASTOR, TREVOR
|
APHIOS CORP:1105999
|
|
|
Molecular Target Focused Discovery of Anticancer Drugs
|
2R01CA090441-06A2
|
$381,250
|
$106,750
|
PETTIT, GEORGE
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
PHASE I AND II CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS
|
N01CN035158-009
|
$1,500,000
|
$150,000
|
CHOW, SHERRY
|
ARIZONA UNIV:1109859
|
|
|
Image-Guided System for Cancer Intervention
|
2R42CA115112-02A2
|
$591,060
|
$591,060
|
Vosburgh, Kirby
|
ASCENSION TECHNOLOGY CORPORATION
|
|
|
CellWell?: A microdevice for single cell analysis
|
7R21CA133551-02
|
$138,750
|
$138,750
|
NETTIKADAN, SAJU
|
ASPERA CORPORATION
|
|
|
Carcinogen Exposure and Adult Cancer Risk
|
5R01CA113560-02
|
$277,400
|
$277,400
|
McQueen, Charlene
|
AUBURN UNIVERSITY AT AUBURN
|
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-19
|
$481,201
|
$76,992
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
|
PDX-1 is a Therapeutic Target for Pancreatic Cancer
|
2R01CA095731-06A1
|
$274,814
|
$274,814
|
BRUNICARDI, FRANCIS
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
NSABP Participating Sites
|
5U10CA118735-03
|
$66,231
|
$7,948
|
CHANG, JENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Molecular Surgeon Symposium on Genetics and Genomics of Pancreatic Cancer
|
1R13CA132572-01
|
$5,000
|
$5,000
|
CHEN, CHANGYI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Obesity, H pylori and Risk of Barrett's Esophagus
|
5R01CA116845-02
|
$562,889
|
$562,889
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans
|
5R01CA125487-02
|
$291,650
|
$291,650
|
El-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Tumor Suppressor Function of Smad4 by Ubiquitin
|
5R01CA108454-05
|
$224,756
|
$112,378
|
FENG, XIN-HUA
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
RNAi-Based Therapy of Hepatocellular Carcinoma
|
5R01CA109574-04
|
$224,720
|
$224,720
|
LI, KAIYI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Reducing Missed And Delayed Diagnoses In Cancer: Lessons From Aviation
|
5K23CA125585-02
|
$141,750
|
$46,778
|
SINGH, HARDEEP
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Regulation of cell growth by RNA binding proteins
|
2R01CA100070-06A1
|
$266,844
|
$266,844
|
TIMCHENKO, NIKOLAI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
The Biology and Diagnosis of Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
|
5R01CA072851-13
|
$326,412
|
$326,412
|
BOLAND, Clement
|
BAYLOR RESEARCH INSTITUTE
|
|
|
JC Virus and Tumor Formation in the Human Colon
|
5R01CA098572-05
|
$260,276
|
$260,276
|
BOLAND, Clement
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Regulation of p21waf1/cip1 by Rho and Ras signaling
|
5R01CA030721-06
|
$182,278
|
$109,367
|
OLSON, MICHAEL
|
BEATSON INSTITUTE FOR CANCER RESEARCH
|
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-25
|
$453,250
|
$72,520
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-10
|
$128,678
|
$18,015
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
BIDMC Research Training Grant in Cancer Radiology
|
5T32CA059367-14
|
$139,719
|
$55,888
|
CLOUSE, MELVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Enhanced RF Tumor Ablation with Liposomal Chemotherapy
|
5R01CA112533-05
|
$382,713
|
$126,295
|
GOLDBERG, S.
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Role of Fibroblasts in Cancer
|
1R01CA125550-01A2
|
$255,000
|
$127,500
|
KALLURI, RAGHU
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Regulation and function of the PKC/PKD signaling pathway
|
5R01CA075134-10
|
$290,144
|
$29,014
|
TOKER, ALEX
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
The role of endothelial to mesenchymal transition (EndMT) in the tumor stroma
|
1K08CA129204-01A1
|
$135,270
|
$67,635
|
ZEISBERG, ELISABETH
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Metabolic Syndrome as Pancreatic Cancer Etiology
|
1R21CA127794-01A2
|
$191,250
|
$191,250
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Role of the Putative Tumor Suppressor PinX1 in the Etiology of Liver Cancer
|
5R01CA122434-03
|
$293,000
|
$293,000
|
ZHOU, XIAO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
A Novel Biotherapeutic Treatment for Pancreatic Cancer
|
1R43CA117283-01A2
|
$99,965
|
$99,965
|
Xu, Kevin
|
BEXION PHARMACEUTICALS, INC.
|
|
|
CellWell?: A microdevice for single cell analysis
|
1R21CA133551-01
|
$30,000
|
$30,000
|
NETTIKADAN, SAJU
|
BIOFORCE NANOSCIENCES, INC.
|
|
|
Cancer Cluster Morphology
|
2R44CA112743-02
|
$375,414
|
$262,790
|
Jacquez, Geoffrey
|
BIOMEDWARE
|
|
|
Cancer targeted therapy through bacterial RNAi
|
1R43CA134097-01
|
$437,294
|
$437,294
|
Li, Chiang
|
BOSTON BIOMEDICAL, INC.
|
|
|
A Risk Prediction Model for Colorectal Cancer Screening
|
1R01CA131197-01A1
|
$389,327
|
$389,327
|
SCHROY, PAUL
|
BOSTON MEDICAL CENTER
|
|
|
Role of Gastrin in the Pathogenesis of Colorectal Cancer
|
5R01CA118992-03
|
$249,738
|
$249,738
|
WOLFE, M
|
BOSTON MEDICAL CENTER
|
|
|
Nanoscale Functional Dendrimer-DNA Assemblies
|
5R21CA125327-02
|
$162,500
|
$162,500
|
GRINSTAFF, MARK
|
BOSTON UNIVERSITY
|
|
|
Hepatic Metabolism of Anti-cancer Drugs
|
3R01CA049248-19S1
|
$50,877
|
$50,877
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY
|
|
|
Hepatic Metabolism of Anti-cancer Drugs
|
5R01CA049248-19
|
$275,637
|
$275,637
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY
|
|
|
Disparities in Lung and Colorectal Cancers
|
1R03CA130067-01A1
|
$81,250
|
$40,625
|
BOEHMER, ULRIKE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Implementing Health Promotion Activities in Native Employers
|
5R21CA124394-03
|
$298,217
|
$74,554
|
BOWEN, DEBORAH
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
NADPH oxidase and pancreatic cancer cell survival
|
5R01CA119025-03
|
$72,009
|
$72,009
|
GUKOVSKAYA, ANNA
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
|
Characterizing disease and treatment response in colon cancer chemoprevention
|
1K05CA131504-01
|
$163,042
|
$163,042
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Total relevant funding to Digestive Diseases for this search: $439,873,191
|
